Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 4/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GLA | P06280 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1353017 | 0.98 | ALOX15 (0.51) | ALOX15HTTMAPTTP53RAB9A | |
| SCHEMBL3575601 | 0.88 | HPGDS (0.54) | ALOX15HTTMAPTTP53RAB9A | |
| SCHEMBL10466162 | 0.87 | HTT (0.67) | ALOX15HTTMAPTRAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1353034 | 0.87 | HPGDS (0.52) | ALOX15HTTMAPTTP53RAB9A | |
| SCHEMBL26798599 | 0.84 | LMNA (0.54) | HTTMAPTTP53RAB9ASMN1; SMN2 | |
| SCHEMBL20118976 | 0.83 | ALOX15 (0.54) | ALOX15HTTMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL1353856 | 0.83 | ALOX15 (0.54) | ALOX15HTTPSMD14MAPK1GAA | |
| SCHEMBL31250404 | 0.83 | ALOX15 (0.54) | ALOX15HTTMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL15517731 | 0.82 | HTT (0.52) | ALOX15HTTMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL12184392 | 0.82 | ALOX15 (0.52) | ALOX15HTTMAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348394-A1 | COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-02 | — | — | US | disclosed |
| US-20230348394-A1 | COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-02 | — | — | US | disclosed |
| CN-116354879-A | Benzamide derivative and application thereof | 中国药科大学 | 2023-06-30 | — | — | CN | disclosed |
| US-8513421-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513421-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| WO-2011146591-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011146591-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110288117-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288117-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288117-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | ALOX15 3098/4885HTT 106/4885MAPT 2029/4885 |
| US-20230348394-A1 | COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHIES | TNNC1, PYGM, GYS1 | ALOX15 3745/4885HTT 1034/4885MAPT 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.